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ABSTRACT 
 
Chapter 1 of this dissertation entails the introduction, aims, objectives and the literature review. Drug 
susceptibility testing of Mycobacterium tuberculosis is time consuming and expensive. Multi-point 
inoculation offers the advantage of testing multiple isolates on a series of solid media with a single 
breakpoint concentration of a drug in each plate or a series of different drug concentrations of one drug. 
We aimed to determine the reproducibility of MIC determination for anti-TB drugs of M. tuberculosis 
isolates using agar dilution with multi-point inoculation and thereafter validating the results by comparing 
it to classic agar dilution on quadrant plates and the MTT assay.  
Chapter 2 contains the manuscript that has been submitted for publication. This manuscript contains a 
brief introduction with the aim and objectives, and a detailed description of the methodology, results and 
discussion. Thirty M. tuberculosis isolates were grown in Middlebrook 7H9 broth with 20% Tween until 
mid-log phase was reached. Agar dilution MICs were determined on Middlebrook 7H10 agar for 11 anti-
TB drugs at concentrations ranging from 128 to 0.125 mg/L. The agar plates were inoculated using a 
multi-point inoculation device with 36 points each delivering 1µL of a suspension of 1×10
4
 cfu/ml. For 
the quadrant plate method and the MTT assay 100 µl of the same suspension was used. All tests were 
done 3 times in triplicate. Agar dilution with multi-point inoculation was found to be reproducible within 
the 11 anti-TB drugs tested and correlated well with agar dilution on quadrant plates and the MTT assay 
for the three anti-TB drugs tested.  
 Chapter 3 entails a brief summary (synthesis) of the discussion found in the above-mentioned 
manuscript. The multi-point inoculation method has potential for wide scale application in breakpoint 
drug susceptibility testing as well as MIC testing of M. tuberculosis isolates. Lastly this dissertation 
contains the required references and appendices.  
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
1.0 Introduction 
 
Mycobacterium tuberculosis is the causative agent of the highly infectious disease tuberculosis (TB), 
which can occur in the lungs (pulmonary TB) and other areas of the human body (extrapulmonary TB) 
(1). The spread of pulmonary TB usually occurs by the air-borne route through expulsion of bacteria 
through coughing or sneezing by individuals infected with M. tuberculosis (1). Immuno-compromised 
individuals are at a higher risk of contracting TB. Therefore, individuals infected with the human 
immunodeficiency virus (HIV), contract TB at higher rates than those that are HIV uninfected (1, 2). 
Aim 
To determine the reproducibility of MIC determination for anti-TB drugs of M. tuberculosis isolates using 
agar dilution with multi-point inoculation and thereafter validating the results by comparing it to agar 
dilution on quadrant plates and the MTT assay. 
Objectives 
1) To establish MICs of 11 anti-TB drugs using 30 M. tuberculosis isolates with varying resistance 
profiles by means of agar dilution using multi-point inoculation 
2) To validate the MICs of agar dilution using multi-point inoculation with agar dilution on quadrant 
plates and the MTT assay. 
 
1.1 Tuberculosis statistics  
 
Globally, TB is the leading cause of death by a communicable disease (1). Of new cases of TB 
approximately 90% occur in adults and 10% children.  In 2015, the estimated number of people that were 
infected with M. tuberculosis was 10.4 million worldwide and 1.8 million of those died from the disease 
(1). The heaviest burden of TB is seen in parts of the world like Asia, the Indian subcontinent and Sub-
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Saharan Africa, due to their population sizes, low socio-economic standing and overall poor health (1, 3, 
4). 
In the 17
th
 century, TB was introduced in South Africa (SA) by European immigrants, arriving 
predominately from Britain and Holland (2). At that time, Europe was experiencing a TB epidemic. SA’s 
mining industries began to develop late in the 19
th
 century and favored the spread of infection which 
happened at a fast rate (2, 5). The miners were exposed to unfortunate working conditions within the 
mines, such as enclosed environments with silica dust exposure. Furthermore, they lived in congested 
hostels and suffered from malnutrition (2), both promoting the transmission of M. tuberculosis bacilli. 
The mine workers that were infected with TB were sent home, generally located in rural areas. This 
would ensure the distribution of TB to other members of their families (2). This cycle of TB infection still 
occurs presently.  
Incidence rates of TB increased steadily during the 20
th
 century, due to factors related to the apartheid 
policy, whereby a poorly equipped health sector was available to tackle the TB epidemic among the black 
population (2). Standard treatment for TB was implemented in SA by the administration of anti-TB drugs 
isoniazid, streptomycin and para-amino-salicyclic acid, during a period of 12-18 months (2, 6). The 
duration of treatment was reduced to 6 months with the introduction of rifampicin and pyrazinamide, due 
to pyrazinamide being known to kill bacilli (containing low metabolic activity) that are not normally 
killed by other drugs (7), but treatment of TB with various anti-TB drugs can take up to 6 months to 2 
years because it is dependent on the type of infection i.e. if susceptible or drug-resistant strains of M. 
tuberculosis are present in patients with TB (3). Incorrect use of anti-TB drugs, high prevalence of 
HIV/AIDS and delays in diagnosing TB gave in the last half of the 20
th
 century rise to multi-drug resistant 
TB (MDR-TB) (8) and this threatened the efficacy of the TB control program (6). The situation became 
even worse with a further development into XDR-TB (9). This occurrence has been seen world-wide (1).   
There are different levels of resistance i.e. high, intermediate and low levels of resistance, which can be 
seen in susceptible, MDR and XDR strains of M. tuberculosis. The levels of resistance effect treatment 
regimens of TB in that the duration of treatment, the dosage of drugs and the variety of drugs changes 
accordingly.  These factors bring about the need for reliable and rapid drug susceptibility tests so that 
correct TB drug regimens can be given to the infected patients.    
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1.2 Diagnosis of Tuberculosis 
 
1.2.1 Clinical Diagnosis 
 
There are many methods of diagnosing TB. These can be separated in 2 categories depending on whether 
the patient has latent or active TB. Latent TB can be detected by the Mantoux test and the Interferon- 
test, whereas methods applied to diagnose active TB depend on where the site of infection is. These 
include physical examination, the posterior-anterior chest X-ray, computed tomography, magnetic 
resonance imaging, ultrasound, echocardiogram and intravenous urography (10). These techniques are 
outside the scope of this dissertation. 
 
1.2.2 Laboratory Diagnosis  
 
Laboratory detection of M. tuberculosis is performed by smear microscopy and culture, which forms the 
WHO approved gold standards (11). Smear microscopy involves staining sputum specimens with an acid-
fast staining technique (12) like Ziehl-Neelsen and auramine staining. Culture methods involve 
inoculation of decontaminated specimens from the site of infection on culture media that promote the 
growth of M. tuberculosis. These include Middlebrook 7H11 and 7H10 agars and 7H9 broth, Lowenstein-
Jenson slants (11, 12) and several others.  While smear microscopy is rapid with a good specificity, its 
sensitivity is low. Culture based methods are highly specific and highly sensitive but have a turnaround 
time of 3 to 8 weeks. Because culture is more demanding and costly, low–income countries rely mainly 
on smear microscopy (11, 13). There are however, newer diagnostic methods that offer shorter turn-
around times but are either too expensive for resource-limited countries or require expertly trained staff to 
conduct these (14, 15). 
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Other methods of laboratory detection of TB include, the MGIT 960, the BacT/ALERT 3D and ESP 
cuture system II which are automated liquid culture systems that uses non-radiometric detection methods 
to measure growth by monitering gas pressure fluctuations, i.e. consumption of oxygen or production of 
carbon dioxide, and these can be measured fluorimeterically or colorimetrically (16).  
The Interferon- release assays (IGRA’s) are able to detect M. tuberculosis infection in vitro by detecting 
interferon-that are released by T-cells upon exposure of M. tuberculosis antigens (17, 18). There have 
been claims that IGRA’s can differentiate between active and latent TB, but this is not entirely true as 
they have shown to contain poor sensitivities in patients that are heavily burdened with M. tuberculosis 
infection or immuno-compromised, thereby making it impossible to see differences in TB infection from 
disease (17, 18).  
 
1.3 Drug susceptibility tests  
 
Drug susceptibility tests (DSTs) for M. tuberculosis are performed to examine drug resistance within 
isolates and to provide guidance in the treatment of TB (3, 19). Like for all bacteria, methods of DSTs for 
M. tuberculosis can be separated into two categories, i.e. phenotypic and genotypic DSTs. Phenotypic 
DSTs include the culture-based methods on solid media such as the proportion method, resistance ratio 
and absolute concentration method (14, 20) and methods that use liquid media with growth indicators. 
These include colorimetric assays such as the Microplate Alamar Blue Assay (MABA), the Resazurin 
Microplate Assay (REMA), the 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
assay and the Nitrate Reductase Assay (NRA). Non-colorimetric assays are the Microscopic Observation 
Drug Susceptibility (MODS) assay, the MGIT 960 DST, the BacT/ALERT 3D DST  and ESP cuture 
system II DST (14). The genotypic DST’s include the Cepheid GeneXpert system and line probe assays. 
 
1.3.1 Phenotypic drug susceptibility testing 
 
The conventional culture-based methods involve a series of anti-TB drugs used against M. tuberculosis 
that are incorporated in a solid medium, usually Middlebrook agar or Lowenstein-Jenson media at the 
critical concentration for the drug tested (21). Media are inoculated with a standard inoculum of M. 
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tuberculosis, incubated at 35 – 37oC, thereafter being observed if growth or inhibition occur by 
comparing with a drug-free control (19). These methods are cheap and reliable but are also labour 
intensive and rely on visualizing the growth of M. tuberculosis, which takes up to 3-6 weeks (14, 20). The 
colorimetric assays mentioned above can be used for detecting M. tuberculosis and be used for drug 
susceptibility testing. The MABA utilizes an oxidation-reduction dye called alamar blue, which is an 
indicator of cellular viability (22). The blue dye is a non-flourescent compound in its oxidized form, that 
changes into a pink flourescent, reduced form, in the presence of viable cells (22). The REMA on the 
other hand uses the salt resazurin, which is reduced in the presence of viable M. tuberculosis bacilli. This 
results in a colour change from  blue to pink (23). The MTT assay detects bacterial dehydrogenase, found 
in viable cells. This enzyme reduces MTT which turns from a yellow soluble substance into purple, 
insoluble formazan crystals. The NRA takes  advantage of the ability of M. tuberculosis to reduce nitrate 
into nitrite, whereby this reduction reaction is determined by the addition of a colour-changing reagent 
called the Griess reagent (24). Drug susceptibility tests of the above kind are performed in liquid media in 
microtitre plates and colour changes are observed visually or measured by means of a spectrophotometer 
(22-24). Although the above-mentioned colorimetric assays yield faster and reliable results, they also 
carry a biohazard risk with the formation of aerosols (14).  
The principle of the Microscopic Observation Drug Susceptibility assay relies on microscopic observation 
of the cord formation displayed by M. tuberculosis which can be viewed at an early stage by microscopy.  
Drug susceptibility testing can be done by comparing growth in medium without an anti-TB drug with 
media that contain drugs at the critical concentration for this method (25, 26). This assay is also rapid and 
cheap but needs experienced and specifically trained staff to conduct (13, 25, 26). It is also prone to 
contamination. 
 Drug susceptibility tests using the MGIT 960, the BacT/ALERT 3D and ESP cuture system II can be also 
done, together with it being diagnostic methods. They are known to confer rapid and reliable results but 
require the use of expensive equipment and expertly trained staff, which makes it unfavourable for 
developing countries (14, 16, 27).  
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1.3.2 Genotypic drug susceptibility testing 
 
The Cepheid GeneXpert System is an automated system that carries out molecular tests for tuberculosis 
case detection, together with its associated DST (28). The Cepheid GeneXpert System detects rifampicin 
resistance in M. tuberculosis by the use of nested real-time PCR. Rifampicin resistance is used as a 
marker for MDR since it is almost always combined with isoniazid resistance (29, 30). The rpoB gene is 
amplified, and probed with molecular beacons specific for mutations in the rifampicin-resistant 
determining region (28). The system utilizes a disposable plastic cartridge, which contains all the reagents 
needed for processing of the specimen and PCR. The addition of a specific bactericidal buffer in this 
process is the only manual step undertaken. The cartridge is then inserted into the GeneXpert device and 
results are retrieved within 2 hours (28). 
Line probe assays e.g. INNO-LIPA Rif TB (Innogenetics, Ghent, Belgium) and Genotype MTBDR plus 
assay (Hain Life Sciences, Nehren, Germany) are utilized for the detection of resistance conferring 
mutations in a variety of genes. It is based on the principle of solid-phase hybridization, whereby PCR is 
used containing biotinylated primers that amplify the target DNA. The biotin is incorporated into the 
amplification product. These are then denatured and hybridized to capture probes attached to the solid 
phase. During the gel electrophoresis that follows, the amplicons migrate over the solid phase. If 
amplicon reaches a matching probe, it binds in that spot. Color detection is then followed by adding a 
conjugate which is streptavidin bound to alkaline phosphatase. This enzyme converts the chromogenic 
substrate into an insoluble product; this forms a colored line at the site where probe and amplicon have 
bound (31).   
 Although these genotypic methods seem rapid and efficient, there are also major drawbacks in that they 
are expensive, detect only identified resistance conferring mutations, require expensive equipment and 
expertly trained staff and detect both viable and dead M. tuberculosis (13, 14, 28).  
 
 
 
1.4 Minimum Inhibitory Concentration  
 
 
Minimum inhibitory concentration (MIC) is the minimal concentration of an antimicrobial that is able to 
inhibit the growth of a target organism. Susceptibility testing of organisms to antimicrobials using MIC 
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determination is done to establish if a particular organism is either susceptible or resistant to a particular 
drug and to determine trends in resistance development (32). Diagnostic laboratories use MICs as a 
confirmation of unusual resistance in organisms and to establish a definitive answer when results from 
other tests are borderline (32). Minimum inhibitory concentration testing can be done to determine the 
efficiency of a particular drug for an entire species. If MIC tests are done for a group of isolates of one 
particular species then the MIC50 and MIC90 of that species can be calculated (33). MIC50 and MIC90 
requires that the number of isolates to be tested results in a statistically significant outcome.   The MIC50 
is the concentration of drug that inhibits 50% of the isolates and MIC90 inhibits 90% of the isolates (33). 
The MIC obtained with a particular method is influenced by the differences in inoculum size, the 
composition of media (solid or liquid), pH and incubation times (7, 19, 34). It is also understood that with 
different methods of determining MICs, there will be a difference in the MIC values. MICs of M. 
tuberculosis isolates on solid media are, for many drugs higher than in liquid media (34).  In this study the 
determination of MIC’s of various anti-TB drugs against M. tuberculosis was done with three different 
DST’s, therefore the understanding of factors that influence the outcome is of crucial importance.  
 
 
1.5 Multi-point Inoculation  
 
1.5.1 The origin of the Multiple Replicating Device 
 
Microbiological procedures often require the sequential transfer of inocula of multiple isolates onto plates 
or into tubes (35).  These procedures are generally performed manually, which can be tedious and prone 
to error. This brought about the development of multiple replicating devices (MRDs) that helped to 
circumvent these challenges and improve precision (35).  The first MRD was described by Garret in 1946, 
where he constructed his very own 10-point inoculating device that had the ability to inoculate agar plates 
at 10 separate points (35). The use of this device shortened the inoculation time to 4 hours for 65 plates, 
giving rise to newer and more practical MRDs (35). Another device was developed and described by Tarr 
in 1958 which had the ability to inoculate up to 25 drops of bacteriophage onto agar plates seeded with 
Staphlococcus aureus, simultaneously (35). More mechanized features (Figure 1) of the MRD device 
were developed for bacteriophage typing (35).       
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Figure 1: Image showing a multiple replicating device (MRD) modified by Lidwell (35) 
 
Multiple replicating devices with a micro-titre format also have been developed. These contain 96 
stainless steel pins. Multiple replicating devices can be used on semi-solid and solid agar plates for assays 
like gas detection, biochemical and motility tests of microorganisms (35). It was noticed that the pins 
could take up approximately 6µl of culture and deliver 2µl onto the agar plates and when this procedure 
was compared to conventional methods; it utilized only 5% of materials and only consumed 10% of time 
(35). Their major applications include antimicrobial susceptibility testing of various isolates of 
microorganisms and screening of compounds that can be used for antimicrobial activity (35). When 
testing different bacterial isolates against streptomycin, Steers et al, developed an aluminum-based 36-pin 
device for antimicrobial susceptibility testing (35, 36).  An image of the device can be seen below (Figure 
2) 
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Figure 2: Image showing a multiple replicating device (MRD) modified by Steers et al (36)
 
 
1.5.2 Use of Multi-point Inoculation with various bacterial species 
 
Multi-point inoculation techniques have been used with species of the family of Enterobacteriaceae for 
inoculation of biochemical and metabolic test media used in identification systems as well as for 
inoculation of drug susceptibility tests (37). When compared to conventional methods of susceptibility 
testing such as disc diffusion methods and test tube methods, the multi-point inoculation technique saves 
time, consumable costs and labor (37). The technique has been demonstrated on clinical isolates with 
rapid results which is good because in clinical settings, quick identification and DST of the infecting 
microorganism allows for the clinician to know which antibiotic regimen to administer or to adjust an 
empirically started regimen. It also can alert infection control teams for potential outbreaks (38).  
Agar dilution with multi-point inoculation is a phenotypic culture-based method for determination of 
MICs that is able to test a large number of isolates at a time, using less materials and cheap equipment 
(35).  
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Manuscript Reference number: JCM01176-17  
 
The development and application of a high throughput methodology to determine MICs of 
Mycobacterium tuberculosis isolates against antimicrobial agents 
Tashmin Rampersad, Mantha Makume, Parveen Sobia, A.Willem Sturm
 
Department of Infection Prevention and Control,  Nelson R Mandela School of Medicine, School of Laboratory of 
Medicine and Medical Science, College of Health Science, University of KwaZulu-Natal, 719 Umbilo Road, 
Durban 4001, South Africa 
 
ABSTRACT 
Drug susceptibility testing (DST) of Mycobacterium tuberculosis is time consuming and expensive. With 
multi-point inoculation, multiple isolates can be tested on solid media with a single breakpoint 
concentration or a series of different drug concentrations to establish the MIC. This reduces consumables 
and labour costs. Multi-point inoculation has not been used with M. tuberculosis. Since its characteristic 
clumping could influence reproducibility of DST using multi-point inoculation, we performed MICs for 
anti-TB drugs of M. tuberculosis isolates using this inoculation technique. The results were compared 
with classic agar dilution on quadrant plates and with the MTT assay.  
Thirty M. tuberculosis isolates were grown in Middlebrook 7H9 broth with 20% Tween until mid-log 
phase. Agar dilution MICs were determined on Middlebrook 7H10 agar for 11 anti-TB drugs at 
concentrations ranging from 128 to 0.125 mg/L. The agar plates were inoculated using a multi-point 
inoculation device with 36 points each delivering 1 µL of a suspension of 1×10
4
 cfu/ml. For the quadrant 
plate method and the MTT assay 100 µl of the same suspension was used. All tests were done three times 
in triplicate.  
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Agar dilution with multi-point inoculation was found to be reproducible with the 11 anti-TB drugs and 
correlated well with agar dilution on quadrant plates and the MTT assay for the three anti-TB drugs 
tested.  
The multi-point inoculation method has potential for wide scale application in breakpoint DST as well as 
MIC testing of M. tuberculosis isolates. 
 
INTRODUCTION 
Tuberculosis (TB) is the leading cause of death by communicable diseases (1). In 2015, the estimated 
number of people that were infected with Mycobacterium tuberculosis was 10.4 million worldwide and 
1.8 million of those died from the disease (1). Developing countries bear the heaviest burden with Asia 
and Africa accounting for 61% and 26% respectively of the number of new cases (2). TB is also the 
leading killer of people infected with HIV, with 35% of HIV related deaths attributed to this infection (2).  
The emergence of multidrug-resistant (MDR) strains threatens the efficacy of TB control programs 
worldwide (3). Factors associated with MDR-TB are HIV infection, control programs not being followed 
appropriately and the delay or absence of laboratory diagnosis. In many under resourced countries the 
diagnosis of TB relies solely on microscopy where drug-susceptibility testing (DST) is not done. With 
classic DST the results become available with considerable delay. To control drug resistant TB, faster and 
cheaper methods are needed (4).    
There are many DST methods available. The gold-standard include culture-based methods such as the 
proportion method, resistance ratio and absolute concentration method (4,5). These methods are labour 
intensive and rely on visualizing growth of M. tuberculosis which takes up to 3 – 6 weeks (5). There are a 
number of colorimetric assays that use reagents which change colour, indicative of growth. These tests 
include the Microplate Alamar Blue Assay (MABA), the Resazurin Microplate Assay (REMA), the 3(4,5-
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dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and the Nitrate Reductase Assay 
(6). The Microscopic Observation Drug Susceptibility (MODS) assay is a rapid and cheap technique 
however it needs experienced and trained staff to conduct (7-9). All of these are rapid assays but they 
pose a biohazard risk with the formation of aerosols (4). The MGIT 960, the BacT/ALERT 3D and ESP 
cuture system  are automated liquid culture systems that use expensive equipment, which is not suitable 
for under-resourced countries (4,10).  
Genotypic DSTs such as the Cepheid GeneXpert system and line probe assays have many drawbacks in 
that the reagents as well as the required equipment are expensive, detect only identified resistance 
conferring mutations, require expertly trained staff and detect both viable and dead M. turberculosis 
(4,11,12).  
The above mentioned drawbacks of DSTs, bring about the need for cheaper and less labor intensive 
procedures. Agar dilution with multi-point inoculation is a phenotypic culture-based method that is able 
to test a large number of isolates at a time, using less materials and cheap equipment (13). We report on 
the reproducibility of agar dilution with multi-point inoculation and compare this method with agar 
dilution on quadrant plates and MTT. 
 
METHODOLOGY 
Inoculum preparation 
 
Thirty Mycobacterium tuberculosis strains with known resistance profiles were used in this study. The 
resistance conferring genes of these isolates have been sequenced previously (14). Two strains were fully 
susceptible, thirteen were MDR and fourteen were XDR. H37Rv was included as a susceptible control. 
Strains were inoculated in 10 ml Middlebrook 7H9 broth containing 10% oleic acid-albumin-dextrose-
catalase (OADC) (Difco Laboratories, Detroit, Mich.), 0.2% glycerol and 0.05% Tween 80 (Appendix A). 
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The broths were incubated at 37⁰C in a shaking incubator until an OD600nm reading of 0.7 – 1 was reached. 
Each strain was sonicated at 5Amps for 20 seconds (Misonix Sonicators) and left undisturbed on the 
bench at room temperature for 15 to 20 minutes to allow remaining clumps to settle. The top-layer was 
then siphoned off and diluted till an OD600nm reading of approximately 0.7. Ethics approval for the study 
was granted by the Biomedical Research Ethics Committee at the University of KwaZulu-Natal 
(BCA274/09). 
 
 
 
Agar-dilution MICs with multi-point inoculation 
 
Agar dilution with multi-point inoculation was used to determine the MIC of M. tuberculosis isolates for 
isoniazid, rifampicin, ethambutol, ethionamide, streptomycin, kanamycin, amikacin, capreomycin, 
ciprofloxacin, ofloxacin, and clofazimine. Double dilutions of the drugs were made in sterile OADC 
(10%) enriched Middlebrook 7H10 agar supplemented with casitone (5.3%) and glycerol (0.2%) 
(Appendix A). The concentrations ranged from 128 mg/L to 0.125 mg/L for all 11 drugs. The agar 
containing the drug dilutions was poured into 90 mm Petri dishes and allowed to solidify. 
The strains were inoculated onto the plates using a Steers replicator, delivering approximately 10 cfu per 
spot. The plates were sealed in gas-permeable plastic bags and incubated in a regular incubator at 37⁰C 
for 21 days. 
Confirmation tests 
To validate the results obtained with multi-point inoculation, two established methods for MIC 
determination were performed with a selection of the strains using three of the antimicrobial drugs: 
isoniazid, streptomycin and kanamycin. These methods were agar dilution on quadrant plates (QPM: 
quadrant plate method) and micro-broth dilution with MTT growth detection.  
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The QPM differed from the multi-point inoculation method in that the surfaces of the agar quadrants were 
flooded with 100µL of the bacterial suspension (approximately 1×10
3
 cfu/quadrant). The plates were 
sealed in gas-permeable plastic bags and incubated in a regular incubator at 37⁰C for 21 days. 
For the MTT, a micro-broth dilution test was performed using the same drug concentrations as for the 
agar dilution methods in 100µL volumes using Difco
TM 
Middlebrook 7H9 broth containing 10% OADC 
(Difco Laboratories, Detroit, Mich.), 0.2% glycerol and 0.05% Tween 80. Hundred microliter of bacterial 
suspension was added to the wells containing the drug dilutions (approximately 1×10
3
 cfu/100µL), 
followed by incubation at 37⁰C for 7 days. All tests were performed in flat-bottom 96 well plates. After 
this incubation period, 20µl of the MTT solution (5µl/mg) (Appendix B) was added to each well followed 
by incubation for a further 24 hours at 37⁰C.  Purple precipitates were then observed to indicate growth. 
A 1:1 solution containing 20% sodium dodecyl sulphate (SDS) and 50% dimethyl formamide (DMF) 
(Appendix B) was added to the wells to dissolve the precipitate to facilitate reading (15). 
Statistical analysis was done using an ordinal regression model (GEE). An intra-class correlation (ICC) of 
1 indicates the replicates are identical. An ICC greater than 0.8 indicates good intra-class correlation. 
 
RESULTS 
Table 1 shows the results of MIC determination of 30 M. tuberculosis isolates against 11 anti-TB drugs 
using agar dilution with multi-point inoculation. The test was performed three times in triplicate in order 
to determine reproducibility. Identical results were found with streptomycin, kanamycin and amikacin 
(ICC=1; p < 0.001).  Poor reproducibility was found with ethambutol (ICC=0.4; p=0.7). The ICC values 
for the seven other drugs showed good correlation with ICC values varying between 0.95 and 0.8. 
To validate the results, 11 of the isolates in triplicate were tested against isoniazid, streptomycin and 
kanamycin, comparing the agar dilution with multi-point inoculation with classic agar dilution in 
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quadrant plates and with the MTT test. The results are shown in table 2. The multi-point inoculation 
technique showed similar results as those presented in Table 1. ICC values for isoniazid obtained with the 
quadrant plate technique were within the satisfactory range (p=0.03) and were good for the other two 
drugs. However, MICs obtained were 2 to 4 dilutions higher than with the multi-point inoculation. The 
MTT test results were highly reproducible for all 3 drugs. The MICs obtained with this method were 
lower than with the quadrant plate method but higher than with multi-point inoculation. 
 
DISCUSSION 
Multi-point inoculation using a Steers replicator is a well-established method to inoculate agar plates with 
multiple bacterial isolates (16). It is mostly used in determining resistance profiles of fastidious organisms 
that need prolonged incubation. Incubation beyond 16 to 24 hours diminishes the reliability of disc 
diffusion susceptibility testing. Since M. tuberculosis is a slow growing organism, incorporation of the 
test drugs in agar or broth is applied for its susceptibility testing. If agar is used, the plates are inoculated 
with a suspension of bacteria which are evenly distributed over the surface. Multi-point inoculation 
allows for testing of multiple strains on one agar plate. The technique is used for the determination of 
MICs of fastidious organisms like Neisseria gonorhhoeae and strict anaerobes. We applied this 
inoculation method with M. tuberculosis and showed good reproducibility with most of the drugs tested. 
Only ethambutol showed poor correlation between tests. This is not surprising because ethambutol is 
known to give inconsistent results in most tests (4, 17).  
We then compared the MICs of three drugs obtained with multi-point inoculation with the results of two 
other methods. The multi-point inoculation technique results shown in table 2 were similar to the previous 
results (table 1), which supported the conclusion that the test is reproducible. It is well known that 
different methods result in differences in MIC values therefore; the differences between the 3 tests can be 
explained by the differences in the inoculum sizes. In both the agar dilution on quadrant plates and the 
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MTT assay, the inoculum size was approximately 1×10
4
 cfu/100µL, whereas in the multi-point 
inoculation technique the inoculum size was approximately 10 cfu per spot. The Steers replicator makes 
use of pins that deliver approximately 1µL of the inoculum onto the agar plates. Therefore the inoculum 
sizes in both the agar dilution on quadrant plates and the MTT assay is approximately 100 times more 
than with the multi-point inoculation technique. Inoculum sizes are known to affect the outcome of drug 
susceptibility tests (18-20). 
Another point to note about the differences in the MICs between the 3 tests is that the two agar dilution 
methods use solid media, as opposed to the MTT assay that uses liquid media. The critical concentrations 
of the anti-TB drugs differ in liquid and solid media (18,21). MICs on solid media, for many drugs are 
higher than in liquid media (18).  The points above could be the reason that the MTT assay MIC results 
were lower than with the quadrant plate method but higher than the multi-point inoculation MICs.  
There are many advantages of agar dilution with multi-point inoculation as compared to the conventional 
agar dilution on quadrant plates, such as the Steers replicator used in the multi-point inoculation technique 
contains 36 pins and wells, which in turn can test 36 different isolates against 1 drug concentration at a 
time. The time taken to conduct an MIC with 12 dilutions using the multi-point inoculation technique on 
30 isolates against 1 drug in triplicate was approximately 1 hour, as compared to the conventional agar 
dilution on quadrant plates in triplicate, took approximately 9 hours. The preparation of media for the two 
methodologies was significantly different as well, where it was a much longer and tedious process to 
make media for the quadrant plate method as compared to the multi-point inoculation method. These 
advantages of the multi-point inoculation method ultimately indicate that it is a highly efficient and 
reproducible drug susceptibility test for M. tuberculosis isolates. 
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Table 1: MIC of 30 M. tuberculosis isolates against 11 anti-TB drugs using agar dilution with multi-
point inoculation 
       
 
No. of isolates Median Range ICC 95% CI P - Value 
Isoniazid  27 16 8 - 32 0.8 0.7 to 0.9 <0.001 
Streptomycin  30 16 0.5 - 128 1 0.9 to 0.9 < 0.001 
Rifampicin  29 128 2 - 128 0.99 0.9 to 0.9 <0.001 
Ethambutol  29 32 4 - 32 0.4 0.06 to  0.7 0.731 
Ethionamide  30 64 2 - 128 0.9 0.8 to 0.9 < 0.001 
Kanamycin  30 4 1 - 128 1 0.9 to 0.9 <0.001 
Amikacin  30 4 0.5 - 128 1 0.9 to 0.9 < 0.001 
Capreomycin  30 4 0.5 - 32 0.95 0.9 to 0.9 < 0.001 
Ciprofloxacin  30 2 0.125 - 4 0.9 0.8 to  0.9 < 0.001 
Ofloxacin  30 1 0.5 - 4 0.89 0.8 to 0.9 < 0.001 
Clofazimine  27 1 0.125 - 16 0.8 0.6 to 0.9 < 0.001 
 
 
 
       
 
 
 
 
 
Difference in no. of isolates for isoniazid, rifampicin, ethambutol and clofazimine is due to a few isolates being contaminated 
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Table 2:  Comparison of MICs of 11 M. tuberculosis isolates determined by three methods.  
     
  
Isoniazid Streptomycin Kanamycin 
Multi-point Inoculation Median (Range) 32 (16-32) 4 (2-128) 4 (4-128) 
 
ICC (95% CI) 0.89 (0.7-0.9) 0.99 (0.9-0.9) 0.99 (0.99-0.99) 
  P - value <0.001 <0.001 <0.001 
Agar dilution on quadrant plates Median (Range) 128 (128-128) 128 (8-128) 16 (8-128) 
 
ICC (95% CI) 0.75 (0.48-0.92) 0.99 (0.99-0.99) 0.99 (0.98-0.99) 
  P - value 0.03 <0.001 <0.001 
MTT Assay Median (Range) 128 (32-128) 8 (2-128) 8 (4-128) 
 
ICC (95% CI) 0.97 (0.9-0.99) 1.0 (0.99-0.99) 0.99 (0.97-0.99) 
  P - value <0.001 <0.001 <0.001 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
 
 
Chapter 3: Synthesis 
 
Multi-point inoculation using a Steers replicator is a well-established method to inoculate agar plates with 
multiple bacterial isolates (36). We applied this inoculation method with M. tuberculosis and showed 
good reproducibility with most of the drugs tested. Only ethambutol showed poor correlation between 
tests. This is not surprising because ethambutol is known to give inconsistent results in most tests (14, 
39).  
We then compared the MICs of three drugs obtained with multi-point inoculation with the results of two 
other methods. The multi-point inoculation technique results shown in table 2 of chapter 2 were similar to 
the previous results (Table 1), which supported the conclusion that the test is reproducible. It is well 
known that different methods result in differences in MIC values therefore; the differences between the 
three methods can be explained by the differences in inoculum size. In both the agar dilution on quadrant 
plates and the MTT assay, the inoculum size was approximately 1×10
3
 cfu/100µL, whereas in the multi-
point inoculation technique the inoculum size was approximately 10 cfu per spot. The Steers replicator 
makes use of pins that deliver approximately 1µL of the inoculum onto the agar plates. The volume of 
inoculum used in both the agar dilution on quadrant plates and the MTT assay is 100L. Therefore, the 
inoculum size is in both these methods is approximately 100 times higher than with the multi-point 
inoculation technique. Inoculum sizes are known to affect the outcome of drug susceptibility tests (7, 19, 
34).  
Another point to note about the differences in the MICs between the three tests is that the two agar 
dilution methods use solid media, as opposed to the MTT assay that uses liquid media. The critical 
concentrations of the anti-TB drugs differ in liquid and solid media (39, 40). MICs on solid media are for 
many drugs higher than in liquid media (39).  The points above could be the reason that the MTT assay 
MIC results were lower than with the quadrant plate method but higher than the multi-point inoculation 
MICs. The overall limitations of the study can be seen by the fact that the number of isolates that were 
tested was less if compared to the number of isolates that the DST methods can accommodate. Also, the 
M. tuberculosis isolates used was stored isolates and not direct clinical isolates. An extension of this study 
is possible where routine DSTs for MIC testing can be used, e.g. the currently established MGIT 960 
DST, together with the multi-point inoculation method can be compared.  
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The advantages of agar dilution with multi-point inoculation compared to agar dilution on quadrant plates 
is the ability to test 36 different isolates against 1 drug at a time resulting in a shorter time period to 
conduct the tests.  Therefore, multi-point inoculation is less labor intensive. The multi-point inoculation 
method proved to be a highly efficient and reproducible drug susceptibility test method for M. 
tuberculosis isolates. 
 
Figure 3: Image showing a multi-point inoculation plate for 11 M. tuberculosis isolates on Middlebrook 
7H10 agar (control plate i.e. contains no drug) 
 
 
Figure 4: Images showing the quadrant plate method for one M. tuberculosis isolate on Middlebrook 
7H10 agar with one drug. 
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Figure 5: Image showing a MTT assay plate containing 2 M. tuberculosis isolates for one drug 
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APPENDIX A  
 
A.1.1 Middlebrook 7H9 Broth  
 
4.7g Middlebrook 7H9 powder  
2ml glycerol  
0.5ml Tween 80  
900ml distilled water  
The above materials were mixed and autoclaved at 121ºC for 15 minutes  
100ml OADC was added once the media was cool. 
 
A.1.2 Middlebrook 7H10 Agar  
 
19g Middlebrook 7H10 powder  
1g casitone  
5ml glycerol  
900ml distilled water  
The above materials were mixed and autoclaved at 121ºC for 15 minutes  
100ml OADC was added once the media was cool. 
 
A.1.3 Formula for drug potency for highest concentration of drug 
 
Drug Potency (mg/L) = Highest concentration required (mg/L) × Volume (mL) / Potency  
 
A.1.4 Amount of powder (drug) required 
 
Mass of drug (g) = Drug Potency (mg/L) × amount of media (mL) × dilution factor × amount of stock 
solution required (mL) 
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APPENDIX B 
 
B.1: MTT Assay reagents  
 
B.1.1: 20% Sodium Dodecyl Sulphate  
4g Sodium Dodecyl Sulphate was dissolved in distilled water to a volume of 20ml. 
 
B.1.2: 50% Dimethylformamide  
10ml Dimethylformamide  
10ml distilled water  
The two reagents were mixed. 
 
B.1.3: MTT Solution  
0.075g MTT powder was dissolved in Phosphate Buffer Saline to a volume of 15ml. 
